enVVeno Medical Corp Cash Flow Conversion Efficiency
enVVeno Medical Corp cash flow conversion efficiency. Based on the latest financial reports, enVVeno Medical Corp (NVNO) has a cash flow conversion efficiency ratio of -0.149x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.39 Million) by net assets ($29.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of enVVeno Medical Corp (2014–2024)
Cash flow conversion efficiency of enVVeno Medical Corp from 2014 to 2024. This chart illustrates how enVVeno Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View enVVeno Medical Corp share price for real-time trading data and today's change.
enVVeno Medical Corp Cash Flow Conversion Ratio Explained
enVVeno Medical Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
enVVeno Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of enVVeno Medical Corp ranked by their cash flow conversion efficiency. Also see enVVeno Medical Corp stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trio Petroleum Corp.
NYSE MKT:TPET
|
-0.060x |
|
Cybergun SA
PA:ALCYB
|
0.310x |
|
E. Pairis S.A
AT:PAIR
|
0.051x |
|
Dotz Nano Ltd
F:57N
|
0.323x |
|
Megaron SA
WAR:MEG
|
0.020x |
|
Sepatu Bata Tbk
JK:BATA
|
-0.374x |
|
Babylon Pump & Power Ltd
AU:BPP
|
0.406x |
|
Pearl Gull Iron Ltd
AU:PLG
|
-0.128x |
Annual Cash Flow Conversion Efficiency for enVVeno Medical Corp (2014–2024)
The table below shows the annual cash flow conversion efficiency of enVVeno Medical Corp from 2014 to 2024. Review free cash flow generation of enVVeno Medical Corp to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $42.16 Million | $-16.84 Million | -0.399x | +2.15% |
| 2023-12-31 | $46.20 Million | $-18.86 Million | -0.408x | -1.21% |
| 2022-12-31 | $38.73 Million | $-15.62 Million | -0.403x | -85.22% |
| 2021-12-31 | $54.40 Million | $-11.85 Million | -0.218x | +79.87% |
| 2020-12-31 | $7.10 Million | $-7.68 Million | -1.082x | +81.84% |
| 2019-12-31 | $989.94K | $-5.90 Million | -5.956x | -90.84% |
| 2018-12-31 | $2.04 Million | $-6.36 Million | -3.121x | -542.63% |
| 2017-12-31 | $-5.96 Million | $-4.20 Million | 0.705x | -93.51% |
| 2016-12-31 | $-283.72K | $-3.08 Million | 10.872x | +858.52% |
| 2015-12-31 | $-1.78 Million | $-2.02 Million | 1.134x | +1874180.75% |
| 2014-12-31 | $-2.01 Million | $121.74 | 0.000x | -- |
About enVVeno Medical Corp
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in … Read more